Reducing ibrutinib dose to maintain BTK inhibition in CLL data model

Reducing the ibrutinib dose from 420 mg per day to 280 mg or even 140 mg per day maintains effective Bruton's tyrosine kinase (BTK) inhibition in patients with chronic lymphocytic leukemia (CLL), according to a published model-based analysis.

Exposure-response analysis of simulated data showed that a dose of 280 mg per day retained greater than 90% BTK occupancy in more than 96% of patients, while a dose reduction to 140 mg per day still achieved a median BTK occupancy of 90% in at least 80% of patients. These results suggest that low-dose ibrutinib may be a viable option for patients experiencing dose-related adverse events without significantly affecting BTK inhibition.

The covalent binding model used in this study accurately predicted the effects of ibrutinib across a range of doses. In patients with typical BTK turnover (half-life of 60 hours), steady-state inhibition of BTK is achieved within 4 days of initiation of treatment. Simulated trough concentrations demonstrated at least a 95% reduction in free BTK concentrations from 140 mg to 560 mg per day compared to baseline. Even in the case of BTK with rapid turnover (half-life of 24 hours), the inhibition rate of BTK in all dosage regimens remained above 88%, supporting the durability of ibrutinib's efficacy.

At steady stateThe proportion of patients with a BTK inhibition rate exceeding 90% varied by dose. While 97% of patients taking 420 mg daily met this threshold, reducing to 280 mg slightly reduced this to 94%, and a further reduction to 140 mg resulted in a response rate of 81%. These results suggest that while 280 mg per day is highly effective, 140 mg still provides substantial suppression, albeit with slightly less consistency across the population. The impact of these dose adjustments on clinical outcomes, such as overall response rate (ORR), progression-free survival (PFS), and overall survival (OS), remains to be determined.

This study also explores the BTK occupancy dynamics of various virtual patients (n=10,000) with variable BTK turnover rates. The dose required to achieve 90% maximal inhibition ranged from 126 mg in patients with slower BTK elimination to 430 mg in patients with faster BTK turnover. These results suggest that some patients may require higher doses to maintain optimal inhibition of BTK, while others may achieve adequate inhibition at lower doses.

Reducing the dose of ibrutinib may be beneficial in patients who experience toxicity and may improve tolerability while maintaining therapeutic efficacy. However, the clinical impact of dose reduction on long-term outcomes warrants further investigation in prospective trials. Future studies should evaluate whether lower doses of ibrutinib can maintain PFS and OS comparable to standard dosing regimens.

The impact of this dose reduction on efficacy endpoints (ORR and PFS) needs to be evaluated in a clinical setting. The ongoingTAILOR study evaluates the impact of a 280 mg dose reduction strategy on the overall benefits/risks of ibrutinib.

Reference materials:https://www.hematologyadvisor.com/news/ibrutinib-btk-inhibintion-chronic-leukemia-cll-treatment-risk/